PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.63
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
No Data
No Data available this quarter, please select a different quarter.
4.08
P/B of 4.08 while RVPH has zero book value. Bruce Berkowitz would examine asset quality advantage.
-16.69
Negative FCF while RVPH shows P/FCF of 0.00. Joel Greenblatt would examine cash flow improvement potential.
-16.77
Negative operating cash flow while RVPH shows P/OCF of 0.00. Joel Greenblatt would examine operational improvement potential.
4.08
Fair value ratio of 4.08 while RVPH has zero value. Bruce Berkowitz would examine valuation methodology.
-6.88%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-5.99%
FCF yield 6-8% - Fair value range. Seth Klarman would verify if yield provides sufficient margin of safety. Check Working Capital efficiency.